Update on the Share Buyback Program and the Liquidity Agreement

Period from 3 September 2026 to 9 September 2026

Share Buyback Program
On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased.

Bekaert announces today that during the period from 3 September 2026 to 9 September 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 57 925 shares.

The table below provides an overview of the transactions under the Program during the period from 3 September 2026 to 9 September 2026:

  Repurchase of shares
Date Market Number of Shares Average Price paid (€) Highest Price
paid (€)
Lowest Price
paid (€)
Total
Amount (€)
3 September 2026 Euronext Brussels 6 000 38.60 38.90 38.25 231 600
  MTF CBOE 6 000 38.61 38.85 38.25 231 660
  MTF Turquoise          
  MTF Aquis          
4 September 2026 Euronext Brussels 5 007 39.26 39.75 38.70 196 575
  MTF CBOE 5 250 39.25 39.65 38.65 206 063
  MTF Turquoise          
  MTF Aquis          
7 September 2026 Euronext Brussels 6 000 38.91 39.45 38.75 233 460
  MTF CBOE 5 668 38.91 39.35 38.70 220 542
  MTF Turquoise          
  MTF Aquis          
8 September 2026 Euronext Brussels 6 000 38.84 39.10 38.50 233 040
  MTF CBOE 6 000 38.84 39.15 38.50 233 040
  MTF Turquoise          
  MTF Aquis          
9 September 2026 Euronext Brussels 6 000 38.46 38.75 38.20 230 760
  MTF CBOE 6 000 38.45 38.75 38.20 230 700
  MTF Turquoise          
  MTF Aquis          
Total   57 925 38.80 39.75 38.20 2 247 440

Liquidity agreement
In relation to the renewed liquidity agreement with Kepler Cheuvreux announced on 25 June 2024, Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 2 700 shares during the period from 3 September 2026 to 9 September 2026 on Euronext Brussels. During the same period, Kepler Cheuvreux on behalf of Bekaert has sold 2 400 shares on Euronext Brussels.

The tables below provide an overview of the transactions under the liquidity agreement during the period from 3 September 2026 to 9 September 2026:

  Purchase of shares
Date Number of Shares Average Price (€) Highest Price (€) Lowest Price (€) Total Amount (€)
3 September 2026 600 38.57 38.70 38.40 23 142
4 September 2026 400 38.70 38.70 38.70 15 480
7 September 2026 500 38.84 38.95 38.70 19 420
8 September 2026 600 38.67 38.80 38.50 23 202
9 September 2026 600 38.30 38.40 38.20 22 980
Total 2 700       104 224

  Sale of shares
Date Number of Shares Average Price (€) Highest Price (€) Lowest Price (€) Total Amount (€)
3 September 2026 400 38.90 39.00 38.80 15 560
4 September 2026 1 400 39.26 39.60 38.90 54 964
7 September 2026 0 0.00 0.00 0.00 0
8 September 2026 200 39.00 39.00 39.00 7 800
9 September 2026 400 38.70 38.80 38.60 15 480
Total 2 400       93 804

The balance held by Bekaert under the liquidity agreement at the end of the period is 26 401 shares.

On 9 September 2026 after closing of the market, Bekaert holds 2 209 483 own shares, or 4.41% of the total number of the outstanding shares.

This information is also made available on the investor relations pages of our website.

Attachment

  • New British-designed and built trains will support the Transpennine Route Upgrade and help decarbonise rail travel across northern England
  • First deployment of Alstom’s Adessia platform in the UK, which offers level access boarding at every door
  • Thousands of UK jobs supported through Alstom’s supply chain
  • Full turnkey solution includes trains, maintenance and charging infrastructure, demonstrating Alstom’s end-to-end rail expertise
  • Contracts worth more than €1.2 billion1 include rolling stock order worth approximately €930 million and maintenance agreements worth around €230 million

11 September 2026 – Alstom, global leader in smart and sustainable mobility, has signed contracts worth €1.2 billion with TransPennine Express (TPE) for the supply and long-term maintenance of a new fleet of battery-electric trains. The British-designed and built trains will transform rail travel across northern England and support the delivery of the Transpennine Route Upgrade (TRU).

The agreements combine a rolling stock contract worth approximately €930 million for 29 five-car battery-electric multiple units (BEMUs) with maintenance contracts valued at around €230 million. The fleet will be delivered from 2032 and will support the ongoing decarbonisation of one of Britain’s most important rail corridors.

The order represents the first deployment of Alstom’s Adessia Stream platform in the UK and will deliver Britain’s first mainline battery-electric train fleet, combining high performance, operational flexibility and sustainable mobility.

“This agreement is a landmark moment for Britain’s railway, and we couldn’t be prouder that the country’s first mainline battery-electric trains will be designed and built in Britain. The fleet will transform journeys across northern England while showcasing the very best of British engineering, innovation and advanced manufacturing,” said Rob Whyte, Managing Director UK at Alstom.

He added: “Beyond the benefits to passengers, this investment will support more than 350 highly skilled jobs in Derby and over 5,500 roles across our UK supply chain, helping create opportunities, develop skills and drive economic growth in communities across the country. As momentum builds behind strengthening UK industry and regional prosperity, this project is a powerful example of what can be achieved by investing in British design, British manufacturing and British talent.”

Devised specifically for the needs of long-distance regional travel, the 121-metre-long trains will operate at speeds of up to 110 mph and provide around 300 seats per train, including a First Class area with catering facilities. The trains will offer passengers modern amenities including Wi-Fi, air conditioning, power and USB-C charging at every set, enhanced luggage provision, real-time passenger information systems, CCTV, dedicated cycle storage and quieter, more comfortable interiors.

Level boarding

A defining feature of the fleet is its level boarding design at every door, helping deliver a more inclusive and accessible passenger experience while reducing station dwell times.

Each train will also include three dedicated wheelchair spaces, two accessible toilets, family-friendly areas and buggy storage.

Furthermore, the trains’ battery technology provides emission-free operations on non-electrified sections of railway. Charging infrastructure will be installed by Alstom at Hull, Scarborough and Saltburn, allowing the Adessia fleet to recharge efficiently during normal operations and supporting TPE’s ambition to operate a fully decarbonised network. Installation of this infrastructure will be a UK-first on the mainline network and follows a similar successful deployment by Alstom in Ireland.

UK jobs and skills

As the home of the Adessia platform, the new trains will be designed, engineered, built and tested at Alstom’s historic Derby Litchurch Lane Works – the UK’s only end-to-end train factory.

The Adessia rolling stock order from TransPennine Express will support more than 350 highly skilled jobs in Derby and over 5,500 roles throughout Alstom’s UK supply chain. Manufacturing is expected to begin in 2028, with the project set to generate at least £360 million in spending with British suppliers.

The maintenance contract – which will support over 100 roles – will run for an initial eight-year period, with the potential for a further eight-year extension, helping maximise fleet availability, reliability and performance throughout its operational life. 

Alstom will train at least 36 apprentices and 36 T Level students over the contract, which is also set to benefit over 1,000 community members each year through the company’s established local engagement framework.

“This landmark investment embodies how GBR will deliver better journeys for people while backing British business. These ambitious upgrades plans mean passengers can wave goodbye to overcrowded, delayed diesel trains and step onboard faster electric trains which are fit for the future,” said Heidi Alexander, Transport Secretary.  

She added: “From Alstom’s factory floor in Derby to supply chains across the country, this deal will deliver growth, jobs, opportunity and better transport links for generations to come.”

The project showcases Alstom’s ability to deliver a complete railway solution, combining rolling stock, maintenance, depot provision and charging infrastructure within a single integrated programme.

“This is a transformational £1.2 billion investment in the future of rail travel across the North, delivering new trains for our customers as well as new infrastructure, new jobs and long-term economic benefits,” said Chris Jackson, Managing Director at TransPennine Express.

He added: “Britain has a proud railway heritage, and this project puts the UK at the forefront of the next generation of cleaner rail technology.”

The new battery-electric fleet will operate on services connecting key destinations across northern England, including Liverpool, Manchester, York, Hull, Scarborough and Saltburn, supporting economic growth and providing passengers with a greener and more comfortable travel experience. The new trains – funded by rail investor Rock Rail – will replace part of TPE’s existing Class 185 fleet.

“I would like to thank TransPennine Express, Alstom and the TRU programme for entrusting Rock Rail with funding and delivering this important project,” said Mark Swindell, Founder at Rock Rail.

He added: “At Rock we care about improving the passenger experience; we feel strongly this project will deliver a step-change in experience, journey times and environmental benefit.” 

A three-year research programme and a £35 million investment culminated in the development of Adessia for the UK – the next evolution of the Aventra train platform, proven at scale across England, with fleets already delivering over 18 billion passenger miles.

With flexible traction options and a lightweight design, Adessia Stream trains deliver required capacities while reducing life-cycle cost. Adessia Stream is a train with accessibility built in, enabling unassisted boarding at 85% of existing UK railway station platforms due to level boarding at every door along the full length of the train – reducing the additional investment needed to adapt platform heights.

With more than 20 years’ experience in battery technology, Alstom is a pioneer in sustainable rail mobility. Alstom was the first rail manufacturer to have both hydrogen and battery trains in commercial operation and continues to expand its portfolio of battery-powered solutions worldwide. A key milestone was reached in February 2026, when the first Coradia Continental battery-electric train entered commercial service for the operator VMS in Germany, followed by the entry into service in July 2026 of France’s first battery-powered trains. These milestones demonstrate how innovative battery technology can accelerate the replacement of diesel trains on non-electrified regional lines.

ALSTOM™, Adessia™ and Adessia Stream™ are protected trademarks of the Alstom Group.

 
About Derby Litchurch Lane Works Derby Litchurch Lane Works is Alstom’s largest global facility, and the UK’s only train factory able to design, engineer, build and test trains for domestic and export markets. Without it, the UK would be the only G7 economy unable to design, engineer, build and test trains for its national railway network.

The site delivered more than 2,660 Aventra carriages for UK train operators between 2017 and 2024. It is currently manufacturing ten additional trains for London’s Elizabeth line, supported by around 40 British suppliers, and is refurbishing CrossCountry’s Voyager train fleet, as part of a £60 million contract.

Following Aventra’s success, Litchurch Lane is now a Centre of Excellence and Alstom’s global hub for the new-generation Adessia train platform.

In 2024, Derby exported the 68th and final monorail train to Cairo under a £2.3 billion UK Export Finance-backed order. These were the first trains exported by a British factory since 2008, when Derby last shipped rolling stock abroad, for South Africa’s Gautrain network.

Litchurch Lane Works was opened by the Midland Railway in 1876 and the city of Derby has been building trains continually since 1839. In 2022, Derby was chosen by the Government as the home of Great British Railways following a vote by the public between contender cities.

About Adessia The backbone of urban mobility, Adessia commuter trains are among the most sustainable ways to travel across cities and surrounding suburbs.

The portfolio includes a wide range of high-floor multiple units and coaches, available in both single- and double-deck configurations and designed to operate in all climatic conditions at speeds of 120-200 km/h on both electrified and non-electrified networks.

As the leading manufacturer of commuter trains, with more than 60 years of experience, Alstom remains committed to further enhancing sustainable operations and the passenger experience.

With more than 48,000 rail cars sold for over 60 commuter systems in nearly 20 countries across Europe, Asia, Africa, the Americas and Australia, Adessia commuter trains deliver comfortable, safe and reliable journeys to more than 20 million passengers every day.

About Alstom Alstom is the pure rail leader, committed to making rail the backbone of sustainable transportation.

Alstom designs and delivers a complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems, end-to-end services, infrastructure, signalling and digital rail solutions.

With 87,800 people in 61 countries, Alstom brings together global expertise and multi-local presence to make every journey smarter, cleaner and more enjoyable.

Together with its partners and customers, Alstom realises the power of rail.

Listed in France, Alstom generated revenues of €19.2 billion for the fiscal year ending 31 March 2026. www.alstom.com

Contacts Press:

HQ

Coralie COLLET – Tel.: +33 (0) 7 63 63 09 62
coralie.collet@alstomgroup.com

 

UK and Ireland
Ben GOODWIN – Tel.: +44 (0) 7935 348 065
ben.goodwin@alstomgroup.com

 

Investor Relations

Cyril GUERIN – Tel.: +33 (0)6 07 89 36 16
cyril.guerin@alstomgroup.com

 

Guillaume GAUVILLE – Tel.: +44 (0)7 588 022 744
guillaume.gauville@alstomgroup.com

 

Jalal DAHMANE – Tel.: +33 (0)6 98 19 96 62
jalal.dahmane@alstomgroup.com

 


1 This order will be booked in the second quarter of Alstom’s fiscal year 2026/27.

Attachment

LEI: 213800NNT42FFIZB1T09 
11 September 2026

Transactions in Own Shares

Foresight Group Holdings Limited (“Foresight”, the “Group”), a leading investment manager in real assets and providing capital for growth, announces that, in accordance with the terms of its current share buyback programme announced on 10 April 2025 (the “Share Buyback”), the Group purchased the following number of its ordinary shares of £nil par value (“Ordinary Shares”) each through JOH Berenberg, Gossler & Co KG (which is trading for these purposes as Berenberg) (“Berenberg”).

Date of purchase: 04 September 2026
Aggregate number of Ordinary Shares purchased: 10,000
Lowest price paid per share (GBp): 471.00
Highest price paid per share (GBp): 478.00
Volume weighted average price paid per share (GBp): 477.080200

Date of purchase: 07 September 2026
Aggregate number of Ordinary Shares purchased: 10,000
Lowest price paid per share (GBp): 476.50
Highest price paid per share (GBp): 479.00
Volume weighted average price paid per share (GBp): 477.859300

Date of purchase: 08 September 2026
Aggregate number of Ordinary Shares purchased: 10,000
Lowest price paid per share (GBp): 474.50
Highest price paid per share (GBp): 481.50
Volume weighted average price paid per share (GBp): 479.485850

Date of purchase: 09 September 2026
Aggregate number of Ordinary Shares purchased: 10,000
Lowest price paid per share (GBp): 474.00
Highest price paid per share (GBp): 478.00
Volume weighted average price paid per share (GBp): 475.255700

Date of purchase: 10 September 2026
Aggregate number of Ordinary Shares purchased: 9,121
Lowest price paid per share (GBp): 469.00
Highest price paid per share (GBp): 479.00
Volume weighted average price paid per share (GBp): 472.005701

Once settled, the purchased shares will be held by the Group in treasury, which means they will have no voting rights while they are held in treasury. Under the current Buyback Programme, an aggregate of 7,431,201 Ordinary Shares have been bought back.

As a result of the above, of the Group’s 116,347,803 Ordinary Shares currently in issue, a total of 111,337,743 have voting rights and 5,010,060 held in treasury and are therefore non-voting. The total number of voting shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in the Group under the FCA’s Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback.

Individual information:

Number of ordinary shares purchased Transaction price (GBp share) Time of transaction (UK Time) Trading Venue    
   
56 471.000 04/09/2026 09:10:48 LSE    
806 477.000 04/09/2026 10:25:14 LSE    
400 477.000 04/09/2026 10:25:14 LSE    
400 477.000 04/09/2026 10:25:14 LSE    
2110 477.000 04/09/2026 10:25:14 LSE    
400 477.000 04/09/2026 10:25:14 LSE    
400 477.000 04/09/2026 10:25:14 LSE    
400 477.000 04/09/2026 10:25:14 LSE    
862 478.000 04/09/2026 10:26:01 LSE    
91 478.000 04/09/2026 10:26:03 LSE    
185 478.000 04/09/2026 10:26:04 LSE    
400 477.000 04/09/2026 10:26:16 LSE    
587 477.000 04/09/2026 10:26:16 LSE    
400 477.000 04/09/2026 10:26:16 LSE    
22 477.000 04/09/2026 10:26:16 LSE    
400 477.000 04/09/2026 10:26:20 LSE    
723 477.000 04/09/2026 10:26:20 LSE    
67 477.000 04/09/2026 10:26:55 LSE    
333 477.000 04/09/2026 10:27:04 LSE    
392 477.000 04/09/2026 10:27:04 LSE    
8 477.000 04/09/2026 10:27:06 LSE    
122 477.000 04/09/2026 10:27:06 LSE    
247 477.000 04/09/2026 10:27:45 LSE    
189 477.000 04/09/2026 10:27:45 LSE    
362 479.000 07/09/2026 08:13:33 LSE    
248 479.000 07/09/2026 08:13:34 LSE    
530 478.500 07/09/2026 09:12:25 LSE    
315 478.000 07/09/2026 09:16:24 LSE    
62 478.000 07/09/2026 09:39:58 LSE    
119 478.000 07/09/2026 09:39:58 LSE    
362 478.000 07/09/2026 09:40:04 LSE    
324 477.000 07/09/2026 09:57:09 LSE    
181 477.500 07/09/2026 12:32:10 LSE    
144 477.500 07/09/2026 12:34:04 LSE    
99 477.500 07/09/2026 12:34:04 LSE    
252 479.000 07/09/2026 13:39:32 LSE    
210 478.000 07/09/2026 14:16:04 LSE    
384 476.500 07/09/2026 14:36:42 LSE    
743 477.000 07/09/2026 15:36:27 LSE    
285 477.000 07/09/2026 15:36:32 LSE    
49 477.000 07/09/2026 15:36:32 LSE    
66 477.000 07/09/2026 15:36:32 LSE    
49 477.000 07/09/2026 15:36:32 LSE    
39 477.000 07/09/2026 15:36:32 LSE    
33 477.000 07/09/2026 15:36:32 LSE    
158 477.000 07/09/2026 15:36:32 LSE    
44 478.000 07/09/2026 15:44:45 LSE    
92 478.000 07/09/2026 15:44:45 LSE    
400 478.000 07/09/2026 15:44:45 LSE    
134 478.000 07/09/2026 15:44:45 LSE    
54 478.000 07/09/2026 15:44:45 LSE    
160 478.000 07/09/2026 15:44:45 LSE    
240 478.000 07/09/2026 15:44:45 LSE    
490 478.000 07/09/2026 15:44:45 LSE    
400 478.000 07/09/2026 15:44:45 LSE    
400 478.000 07/09/2026 15:44:45 LSE    
196 478.000 07/09/2026 15:44:45 LSE    
400 478.000 07/09/2026 15:44:45 LSE    
400 478.000 07/09/2026 15:44:45 LSE    
76 478.000 07/09/2026 15:44:45 LSE    
324 478.000 07/09/2026 15:44:45 LSE    
76 478.000 07/09/2026 15:44:45 LSE    
61 478.000 07/09/2026 15:44:45 LSE    
339 478.000 07/09/2026 15:44:45 LSE    
61 478.000 07/09/2026 15:44:45 LSE    
400 478.000 07/09/2026 15:44:45 LSE    
239 478.000 07/09/2026 15:44:45 LSE    
1534 479.000 08/09/2026 08:20:16 LSE    
1532 480.500 08/09/2026 08:24:43 LSE    
182 481.500 08/09/2026 08:25:58 LSE    
796 480.500 08/09/2026 08:26:11 LSE    
452 480.000 08/09/2026 08:30:35 LSE    
1123 478.500 08/09/2026 08:38:56 LSE    
182 475.000 08/09/2026 09:11:58 LSE    
182 474.500 08/09/2026 09:50:04 LSE    
699 477.500 08/09/2026 10:16:43 LSE    
7 476.500 08/09/2026 10:18:56 LSE    
1470 480.000 08/09/2026 10:44:58 LSE    
292 479.500 08/09/2026 10:44:58 LSE    
424 481.000 08/09/2026 11:49:55 LSE    
92 481.000 08/09/2026 11:49:55 LSE    
238 480.500 08/09/2026 11:55:08 LSE    
200 479.500 08/09/2026 12:20:59 LSE    
463 480.000 08/09/2026 12:47:03 LSE    
14 479.500 08/09/2026 13:14:04 LSE    
76 479.500 08/09/2026 13:14:04 LSE    
42 479.500 08/09/2026 13:14:04 LSE    
595 476.000 09/09/2026 08:00:20 LSE    
227 474.500 09/09/2026 08:09:22 LSE    
181 474.500 09/09/2026 08:28:28 LSE    
181 478.000 09/09/2026 08:31:07 LSE    
1517 477.000 09/09/2026 08:33:56 LSE    
761 475.500 09/09/2026 08:39:27 LSE    
760 475.500 09/09/2026 08:39:27 LSE    
1531 474.500 09/09/2026 08:44:51 LSE    
1543 474.000 09/09/2026 08:50:32 LSE    
1489 475.500 09/09/2026 09:03:04 LSE    
1215 474.500 09/09/2026 09:05:08 LSE    
366 479.000 10/09/2026 08:05:00 LSE    
244 479.000 10/09/2026 08:05:00 LSE    
392 477.500 10/09/2026 08:28:17 LSE    
183 476.000 10/09/2026 08:30:52 LSE    
38 475.000 10/09/2026 08:41:42 LSE    
183 475.000 10/09/2026 09:02:34 LSE    
138 473.500 10/09/2026 09:34:39 LSE    
240 473.500 10/09/2026 10:42:03 LSE    
183 473.500 10/09/2026 10:42:11 LSE    
183 474.000 10/09/2026 11:41:08 LSE    
376 473.500 10/09/2026 11:42:10 LSE    
51 471.500 10/09/2026 13:04:07 LSE    
144 471.500 10/09/2026 13:04:07 LSE    
240 471.000 10/09/2026 14:38:59 LSE    
160 471.000 10/09/2026 14:38:59 LSE    
400 471.000 10/09/2026 14:51:12 LSE    
100 471.000 10/09/2026 14:51:12 LSE    
261 471.000 10/09/2026 14:51:12 LSE    
21 471.000 10/09/2026 14:51:12 LSE    
379 471.000 10/09/2026 14:55:24 LSE    
400 471.000 10/09/2026 14:55:24 LSE    
302 471.000 10/09/2026 14:55:24 LSE    
105 471.000 10/09/2026 14:55:24 LSE    
295 471.000 10/09/2026 14:55:24 LSE    
105 471.000 10/09/2026 14:55:24 LSE    
295 471.000 10/09/2026 14:55:24 LSE    
105 471.000 10/09/2026 14:55:24 LSE    
193 471.000 10/09/2026 14:55:24 LSE    
458 470.000 10/09/2026 15:01:01 LSE    
184 469.500 10/09/2026 15:18:46 LSE    
262 470.500 10/09/2026 15:22:15 LSE    
184 470.500 10/09/2026 15:31:33 LSE    
184 470.000 10/09/2026 15:54:35 LSE    
68 469.000 10/09/2026 16:01:27 LSE    
400 470.000 10/09/2026 16:08:03 LSE    
400 470.000 10/09/2026 16:08:03 LSE    
400 470.000 10/09/2026 16:08:03 LSE    
400 470.000 10/09/2026 16:08:03 LSE    
16 470.000 10/09/2026 16:08:03 LSE    
16 470.000 10/09/2026 16:08:09 LSE    
67 469.000 10/09/2026 16:27:47 LSE    

For further information please contact:

Foresight Group Investors
Ben McGrory
+44 (0) 7443 821577
ir@foresightgroup.eu

Berenberg (Joint Corporate Broker)
James Felix / John Welch / Dan Gee-Summons
+44 (0) 203 753 7800

H-Advisors Maitland
Sam Cartwright / Audrey Da Costa
+44 (0) 782 725 4561 / +44 (0) 781 710 5562
Foresight@h-advisors.global

About Foresight Group Holdings Limited

Founded in 1984, Foresight is a leading investment manager in real assets and capital for growth, operating across the UK, Europe, and Australia.

With decades of experience, Foresight offers investors access to attractive investment opportunities at the forefront of change. Foresight actively builds and grows investment solutions to support the energy transition, decarbonise industry, enhance nature recovery and realise the economic potential of ambitious companies.

A constituent of the FTSE 250 index, Foresight’s diversified investment strategies combine financial and operational skillsets to maximise asset value and provide attractive returns to its investors. Its wide range of private and public funds is complemented with a variety of investment solutions designed for the retail market.

Foresight is united by a shared commitment to build a sustainable future and grow thriving companies and economies.

Visit https://foresight.group for more information.

Follow us on LinkedIn for key updates. 

ICG Enterprise Trust plc (the “Company”)

11 September 2026

Transaction in Own Shares

The Company announces that on 10 September 2026 it bought back 10,000 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1431 pence per share.

Further details are set out below:

  • Number of shares held as treasury shares following settlement of this purchase: 3,144,402
  • Total shares in issue excluding treasury shares following settlement of this purchase: 60,409,790

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 11 September 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares

10 September 2026
Number of Shares purchased

50,000 Class A Shares
Highest price/lowest price paid

£14.70 / £14.70
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 38,941,702‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 38,941,702 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger
Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger’s investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again this past year, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards.
Data as of March 31, 2026.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

All Neuberger figures are as of March 31, 2026, unless otherwise noted, and are subject to change without notice. The firm data, including employees and assets under management, reflect the collective data of the various affiliated investment advisors who are subsidiaries of Neuberger Berman Group LLC. The company history/timeline includes the history of all the company’s subsidiaries, including predecessor companies and acquisitions.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

Octopus Titan VCT plc

Net Asset Value

The Board of Octopus Titan VCT plc (the “Company”) has reviewed the portfolio and announces that, as at 30 June 2026, the unaudited Net Asset Value (“NAV”) of the Company was 45.1 pence per share, representing an increase of approximately 1.3% from 44.5 pence per share as at 31 December 2025.

The increase reflects a combination of positive valuation movements across parts of the portfolio, including from companies demonstrating strong underlying performance, and gains realised on disposals during the period. These were partly offset by valuation reductions elsewhere in the portfolio, including the impact of continued pressure on comparable market multiples.

Further details will be provided in the half-year report due to be released later in September 2026.

For further information please contact:

Rachel Peat
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800A67IKGG6PVYW75

BPCE S.A.
Legal Entity Identifier (LEI): 9695005MSX1OYEMGDF46

Société anonyme à directoire et conseil de surveillance

Share capital: €242 487 090

Registered office: 7, promenade Germaine Sablon, 75013 Paris, France

RCS Paris 493 455 042

(the « Issuer »)

NOTICE OF EARLY REDEMPTION TO THE NOTEHOLDERS

dated 11 September 2026

in relation to the

BPCE €900,000,000 Contingent Tier 2 Capital Subordinated Fixed Rate Resettable Notes due January 2042 issued as Series no.: 2021-13

(ISIN: FR0014005V34) (the “Notes”)

On 13 October 2021, the Issuer issued the Notes with a prospectus dated 11 October 2021 which received approval no. 21-438 from the Autorité des marchés financiers (the “Prospectus”), which includes the terms and conditions of the Notes (the “Conditions”). Capitalized terms not specifically defined in this notice shall have the meaning given to them in the Conditions.

Notice is hereby given that, pursuant to Condition 7.2 (Redemption at the option of the Issuer) of the Conditions, the Issuer will redeem the Notes in full on 13 October 2026 (the “Optional Redemption Date” ).

An Euronext Paris notice regarding the delisting of the Notes will be published, with effect on such date accordingly.

At the Optional Redemption Date, the Issuer will pay to each noteholder the principal amount of such Notes together with any interest accrued up to (but excluding) the Optional Redemption Date (the “Optional Redemption Amount”).

Fiscal Agent, Principal Paying Agent and Calculation Agent:

BNP PARIBAS (acting through its Securities Services business)

Les Grands Moulins de Pantin

9, rue du Débarcadère

93500 Pantin

France

By: BPCE

Attachment

Press Release
Nicox Announces NCX 470 NDA in China Accepted for Review
  • Acceptance of the NCX 470 dossier initiates the review process
  • Regulatory decision expected within 12-18 months from the August submission
  • Q&A on Ocumension available on Nicox’s website

September 11, 2026 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive licensee in China, Ocumension Therapeutics, has received confirmation from China’s National Medical Products Administration (NMPA) that the NCX 470 (also referred to as OT-301 by Ocumension) New Drug Application (NDA) in China has been accepted for review. This acceptance initiates the review of the NDA by the NMPA. Nicox had previously announced the submission of the NCX 470 NDA in China as a treatment to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

“The acceptance for review of the NCX 470 NDA in China initiates the examination process and is another key step towards its commercialisation in this territory. We look forward to continuing to work with the Ocumension team as they prepare for a future launch.” said Gavin Spencer, Chief Executive Officer of Nicox.

Ocumension’s Press release is here.

Ocumension has paid Nicox license fees of €18 million for the rights to develop and commercialise NCX 470 in the Chinese, Korean and Southeast Asian markets, contributed 50% of the Denali clinical trial costs and is one of Nicox’s principal shareholders. Nicox will receive tiered royalties on sales of NCX 470 made by Ocumension ranging from 6% to 12%. Ocumension already has an ophthalmology sales force in place throughout China and is therefore well-positioned for a rapid launch of NCX 470.

There is no fixed period for approval of a pharmaceutical product in China, however the review process typically takes 12 to 18 months following submission. The decision on NCX 470 in China is expected after the decision by the U.S. FDA, who have assigned the PDUFA date1 for 30 April 2027.  

Key Upcoming NCX 470 Milestones

  • Japan Phase 3 clinical trials results: trials ongoing  
  • NDA approval in the U.S.: PDUFA date 30 April 2027
  • U.S. Launch: expected in H2 2027, subject to NDA approval
  • NDA decision in China: Submission made in August 2026, accepted for review on 10 September 2026
About NCX 470
NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs.

NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world.  Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX).

For more information www.nicox.com

Analyst coverage
H.C. Wainwright & Co        Yi Chen           New York, U.S.  
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts  
Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com
 
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2025” which are available on Nicox’s website (www.nicox.com).

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00


1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).

Attachment

Lille (France), Cambridge (Massachusetts, United States), September 11, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit GENFIT to the CAC Mid 60 and SBF 120 indices.

These changes will become effective after the market closes on Friday, September 18, 2026.

Pascal Prigent, CEO of GENFIT, commented: “We are pleased to be added to the Euronext CAC Mid 60 and SBF 120 indices. This inclusion comes after a positive momentum for GENFIT and growing investor confidence in our strategy and our ability to execute on it. This milestone further validates our continued commitment to bringing innovative therapies and diagnostic solutions to patients with rare and life-threatening liver diseases while creating long-term value for our shareholders.”

The CAC Mid 60 and SBF 120 are among the most widely-followed indices on Euronext Paris, representing mid-sized listed companies and a broader selection of 120 major securities, respectively. The company’s admission to the SBF 120 reflects its increased market capitalization, liquidity and visibility. It is expected to enhance the company’s profile among institutional investors and confirms its growing relevance within the French equity market.

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.1   Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements regarding the expected benefits of GENFIT’s inclusion in the CAC Mid 60 and SBF 120 indices, investor interest in the Company, the Company’s strategic positioning, its ability to execute on its strategy, its future growth prospects, the advancement of its pipeline and the creation of long-term value for shareholders. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Inclusion in stock market indices does not guarantee increased liquidity, sustained investor interest, share price appreciation or future operating performance. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel: +33 3 2016 4000 |
jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media

Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com 


1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

NOTICE

Elis announces the early redemption on 13 October 2026 of its €380,000,000 2.25% bonds convertible into new shares and/or exchangeable for existing shares
due 2029 (OCEANEs)
ISIN FR001400AFJ9 (the “Bonds”)

Puteaux, September 11, 2026 – Elis (the “Company”) informs the holders of the Bonds (the “Bondholders”) that it will proceed with the early redemption on 13 October 2026 (the “Early Redemption Date”) of all Bonds outstanding on such date, pursuant to the first paragraph of Condition 1.10.1.3, “Early redemption at the Company’s option”, of the terms and conditions of the Bonds dated 22 September 2022 (the “Terms and Conditions”).

Capitalised terms that are not otherwise defined in this notice shall have the meanings given to them in the Terms and Conditions.

Unless the Bondholders exercise their Conversion/Exchange Right in accordance with the Terms and Conditions, the Company will redeem in cash on the Early Redemption Date each Bond outstanding on such date at a price per Bond equal to EUR 100,129.45 (the “Early Redemption Price”), being the par value of each Bond (EUR 100,000) together with EUR 129.45 in accrued interest calculated from (and including) 22 September 2026 to (but excluding) the Early Redemption Date.

In accordance with the first paragraph of Condition 1.10.1.3 of the Terms and Conditions, at the Company’s request, Conv-Ex Advisors Limited, acting as Calculation Agent in respect of the Bonds, has verified that the arithmetic mean, calculated over a period of 20 consecutive Trading Days from (and including) 11 August 2026 to (and including) 7 September 2026, selected by the Company from among the 40 consecutive Trading Days from (and including) 17 July 2026 to (and including) 10 September 2026, of the products, in respect of each such Trading Day, of (i) the Volume-Weighted Average Price of the Shares on that Trading Day and (ii) the Conversion/Exchange Ratio applicable on that Trading Day, exceeded 130% of the par value of each Bond.

In accordance with Conditions 1.10.1.3 and 2.3 of the Terms and Conditions, a Bondholder may exercise its Conversion/Exchange Right in respect of any Bond held by it, provided that the relevant Request Date in respect of such exercise falls no later than 2 October 2026 (being the seventh (7th) Business Day preceding the Early Redemption Date), and that such exercise is otherwise made in accordance with the Terms and Conditions.

Bondholders wishing to exercise their Conversion/Exchange Right should contact the financial intermediary holding their Bonds in a securities account sufficiently in advance so that all requirements for a valid exercise, including receipt of the exercise request and transfer of the corresponding Bonds, are completed by the applicable deadline. The centralising agent for the Bonds is Uptevia, Cœur Défense Tour A – 90-110 Esplanade du Général de Gaulle 92400 Courbevoie (the “Centralising Agent”).

Each Bond in respect of which the Conversion/Exchange Right has not been validly exercised by the applicable deadline will be redeemed in cash at the Early Redemption Price on the Early Redemption Date.

As of the date of this notice, 3,800 Bonds remain outstanding out of a total of 3,800 Bonds initially issued. The Conversion/Exchange Ratio is currently equal to 6,256.8564 Shares per Bond. Assuming that all Bondholders exercise their Conversion/Exchange Right, a maximum of 23,776,054 Elis shares could be delivered, representing approximately 10.21% of the Company’s current share capital, subject to any subsequent adjustment of the Conversion/Exchange Ratio in accordance with the Terms and Conditions. The Company intends to use the existing Shares it holds following the completion of its share buyback program on 9 July 2026, thereby limiting the number of newly issued Shares that may be required. Bondholders validly exercising their Conversion/Exchange Right may receive newly issued Shares and/or existing Shares, as determined by the Company. Settlement and delivery of Shares will occur in accordance with the Terms and Conditions and the instructions of the Centralising Agent.

IMPORTANT NOTICE

The early redemption of the Bonds may not be accepted in any jurisdiction where such redemption would be prohibited or restricted by applicable law, or by residents of any such jurisdiction. No document relating to the exercise of the early redemption option may be transmitted, directly or indirectly, in or into any such jurisdiction or to any such person.

This notice does not constitute an offer to sell, a solicitation of an offer to purchase, or an offer to purchase any securities of Elis in any jurisdiction.

Contacts

Nicolas Buron
Director of Investor Relations, Financing & Treasury
Phone: + 33 (0)1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux
Investor Relations
Phone: + 33 (0)1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.